Tzield Side Effects

Generic name: teplizumab

Medically reviewed by Drugs.com. Last updated on Jun 19, 2023.

Note: This document contains side effect information about teplizumab. Some dosage forms listed on this page may not apply to the brand name Tzield.

Applies to teplizumab: intravenous solution.

Serious side effects of Tzield

Along with its needed effects, teplizumab (the active ingredient contained in Tzield) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking teplizumab:

More common

Black, tarry stools
bleeding gums
blood in the urine or stools
chest pain or tightness
cough or hoarseness
dizziness
fever or chills
headache
itching, pain, redness, swelling, tenderness, or warmth on the skin
loss of appetite
lower back or side pain
muscle aches or pain
nausea
painful or difficult urination
pale skin
pinpoint red spots on the skin
rash
red, tender, or oozing skin at the incision
sneezing
sore throat
sores, ulcers, or white spots on the lips or in the mouth
stomach pain
stuffy or runny nose
swollen glands
trouble breathing
unusual bleeding or bruising
unusual tiredness or weakness

Less common

Diarrhea
difficulty swallowing
faintness
fast heartbeat
general feeling of discomfort or illness
joint pain or swelling
muscle pain
puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
vomiting

Rare

Large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs

For Healthcare Professionals

Applies to teplizumab: intravenous solution.

Dermatologic

Very common (10% or more): Rash (48%)

Common (1% to 10%): Urticaria

Uncommon (0.1% to 1%): Angioedema^[Ref]

Gastrointestinal

Common (1% to 10%): Diarrhea, nausea^[Ref]

Hematologic

Very common (10% or more): Anemia (27%), leukopenia (21%), lymphopenia (74%), thrombocytopenia (13%)

Common (1% to 10%): Neutropenia^[Ref]

Hepatic

Common (1% to 10%): Increased alanine aminotransferase^[Ref]

Hypersensitivity

Common (1% to 10%): Cytokine Release Syndrome (CRS)^[Ref]

Immunologic

Common (1% to 10%): Serum sickness^[Ref]

Metabolic

Very common (10% or more): Liver transaminase elevations (56%)^[Ref]

In patients treated with this drug who experienced CRS, 56% of them reported increased liver transaminase levels: 64% were up to 2.5 times upper limit of normal (ULN), 32% were more than 2.5 to 5 times ULN, and 4.5% were 5-10 times ULN.^[Ref]